PRTC — PURETECH HEALTH PLC (Healthcare >> Biotechnology)
PRTC FAQ
What is PRTC's P/E ratio?
PURETECH HEALTH PLC (PRTC) currently trades at a P/E ratio of 4.41.
What is PRTC's ROE?
PURETECH HEALTH PLC reports a Return on Equity (ROE) of -17.94%.
What is PRTC's dividend yield?
PURETECH HEALTH PLC offers a dividend yield of 0.00%.
What is PRTC's Deepscope Quality Score?
Deepscope rates PRTC's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PRTC?
Deepscope's AI Timing Score for PRTC is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PRTC belong to?
PURETECH HEALTH PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 16.86
Price
-1.19
(-6.58%)
Day Change
|
|
|---|
PRTC, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 72 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 16.86 |
| PBV / Sector |
1.37 / 4.63
GOOD
|
| Earning Per Share | -2.25 |
| PE / Sector |
4.41 / 17.43
GREAT
|
| PEG or PE/Growth / Sector |
-0.01 / 0.53
|
| Average 1M Daily Value |
0.29 M
GREAT
|
| Average 1W Daily Value |
0.07 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:07 |
| Symbol | PRTC |
| Name | PURETECH HEALTH PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 24.34 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 419.90 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 6 Tide Street, Boston, MA, United States, 02210
Phone: 617 482 2333
Website: https://www.puretechhealth.com
Employees: 56
Sector: Healthcare >> Biotechnology
Description: PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google